{"url_path":"/sec/cprx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001369568-26-000002-index.html","accession_number":"0001369568-26-000002","cik":"0001369568","ticker":"CPRX","issuer_name":"CATALYST PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001369568-26-000002-index.html","primary_entity_key":"0001369568","primary_entity_name":"CATALYST PHARMACEUTICALS, INC."},"word_count":211,"has_tables":true,"body_markdown":"ITEM 6. EXHIBITS\n\n \n\n2.1\n\n[Agreement and Plan of Merger, dated as of May 6, 2026, by and among the Company, Parent and Merger Sub, incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on May 7, 2026 (File No. 001-33057)](https://www.sec.gov/Archives/edgar/data/1369568/000119312526210518/d90722dex21.htm)\n\n \n\n \n\n31.1\n\n[Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002](cprx-ex31_1.htm)\n\n \n\n \n\n31.2\n\n[Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002](cprx-ex31_2.htm)\n\n \n\n \n\n32.1\n\n[Certification of Principal Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002](cprx-ex32_1.htm)\n\n \n\n \n\n32.2\n\n[Certification of Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002](cprx-ex32_2.htm)\n\n \n\n \n\n101.INS\n\nInline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document\n\n \n\n \n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n104\n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n \n\n52\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURES\n\nPursuant to the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\nCatalyst Pharmaceuticals, Inc.\n\n \n\n \n\n \n\nBy:\n\n \n\n/s/ Michael W. Kalb\n\n \n\n \n\nMichael W. Kalb\n\n \n\n \n\nExecutive Vice President and Chief Financial Officer\n\n \n\nDate: May 11, 2026\n\n53"}